CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announces that it has acquired all device technology assets from the proprietary portfolio of SipNose Nasal Delivery Systems, a company focused on intranasal delivery platforms for local, systemic and central nervous system indications..

伊利诺伊州水晶湖。--（商业新闻短讯）--Aptar Pharma是药物输送系统，服务和活性材料科学解决方案的全球领导者，今天宣布，它已从SipNose鼻腔输送系统的专有投资组合中收购了所有设备技术资产，该公司专注于局部，全身和中枢神经系统适应症的鼻内输送平台。。

SipNose offers a variety of devices that are designed and adapted to fit a wide range of therapies and offer the opportunity to precisely target areas of the nasal cavity to enable enhanced systemic, local or even direct-to-brain delivery.

SipNose提供了多种设备，这些设备经过设计和调整，可适用于多种治疗方法，并提供了精确定位鼻腔区域的机会，从而增强了全身，局部甚至直接向大脑的输送。

SipNose’s expanded innovative delivery systems, which include liquid and dry powder intranasal delivery, will further strengthen Aptar Pharma’s nose-to-brain pathway expertise and fuel additional development and new scientific research. Acquiring SipNose’s assets will expand Aptar Pharma’s patent product portfolio and support new product development to further supplement intranasal delivery applications and R&D innovation platforms..

SipNose扩展的创新输送系统，包括液体和干粉鼻内输送，将进一步加强Aptar Pharma的鼻-脑通路专业知识，并推动额外的发展和新的科学研究。收购SipNose的资产将扩大Aptar Pharma的专利产品组合，并支持新产品开发，以进一步补充鼻内递送应用和研发创新平台。。

Reenal Gandhi, Business Development Director, Aptar Pharma, commented, “SipNose is focused on development and innovation in intranasal drug delivery. Integrating these assets into our portfolio underlines Aptar Pharma’s continued expansion into the nasal drug delivery space.”

Aptar Pharma业务发展总监Reenal Gandhi评论道：“SipNose专注于鼻内给药的开发和创新。将这些资产整合到我们的投资组合中，突显了Aptar Pharma在鼻内给药领域的持续扩张。”

“Our nasal systems’ proven capabilities have brought added value to our customers and further convenience for patients worldwide for over 30 years,” added Alex Theodorakis, President Aptar Pharma Prescription. “As the nasal market looks to develop new drugs to address unmet patient needs, this transaction will enhance Aptar’s portfolio of nasal drug delivery systems with a focus on CNS diseases.”.

Aptar Pharma President Alex Theodorakis补充道：“30多年来，我们的鼻腔系统经过验证的功能为我们的客户带来了附加价值，并为全球患者带来了进一步的便利。”。“随着鼻腔市场寻求开发新药以满足未满足的患者需求，这笔交易将增强Aptar的鼻腔给药系统组合，重点关注中枢神经系统疾病。”。

About SipNose

关于SipNose

Founded in 2011, SipNose specializes in nasal drug delivery for delivering drugs. SipNose combines expertise in technology, engineering, medical applications and science together with managing and product development proficiency. For more information, visit www.sipnose.com.

SipNose成立于2011年，专门从事鼻腔给药。SipNose将技术、工程、医学应用和科学方面的专业知识与管理和产品开发能力相结合。有关更多信息，请访问www.sipnose.com。

About Aptar Pharma

关于Aptar Pharma

Aptar Pharma is part of AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world.

Aptar Pharma是AptarGroup，Inc.的一部分，AptarGroup是药物和消费品剂量、配药和保护技术的全球领导者。亚太地区服务于许多有吸引力的终端市场，包括制药、美容、食品、饮料、个人护理和家庭护理。Aptar利用市场专业知识、专有设计、工程和科学为许多世界领先品牌创造创新解决方案，进而为世界各地数百万患者和消费者的生活、外表、健康和家庭带来有意义的改变。

Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com..

Aptar总部位于伊利诺伊州水晶湖，在20个国家拥有13000多名专职员工。有关更多信息，请访问www.aptar.com。。